BR112016025787A2 - Formulação farmacêutica compreendendo gencitabina-[fenil- (benzóxi-l-alaninil)]-fosfato, seu uso no tratamento de câncer, método de preparação e kit compreendendo a mesma - Google Patents

Formulação farmacêutica compreendendo gencitabina-[fenil- (benzóxi-l-alaninil)]-fosfato, seu uso no tratamento de câncer, método de preparação e kit compreendendo a mesma

Info

Publication number
BR112016025787A2
BR112016025787A2 BR112016025787A BR112016025787A BR112016025787A2 BR 112016025787 A2 BR112016025787 A2 BR 112016025787A2 BR 112016025787 A BR112016025787 A BR 112016025787A BR 112016025787 A BR112016025787 A BR 112016025787A BR 112016025787 A2 BR112016025787 A2 BR 112016025787A2
Authority
BR
Brazil
Prior art keywords
gencitabin
alaninyl
benzoxy
cancer
kit
Prior art date
Application number
BR112016025787A
Other languages
English (en)
Other versions
BR112016025787B1 (pt
Inventor
Griffith Hugh
Kennovin Gordon
Original Assignee
Nucana Biomed Ltd
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1411253.6A external-priority patent/GB201411253D0/en
Priority claimed from GBGB1417646.5A external-priority patent/GB201417646D0/en
Application filed by Nucana Biomed Ltd, NuCana plc filed Critical Nucana Biomed Ltd
Publication of BR112016025787A2 publication Critical patent/BR112016025787A2/pt
Publication of BR112016025787B1 publication Critical patent/BR112016025787B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112016025787-1A 2014-06-25 2015-06-25 Formulação farmacêutica compreendendo gencitabina-[fenil- (benzóxi-l-alaninil)]-fosfato, seu uso no tratamento de câncer, método de preparação e kit compreendendo a mesma BR112016025787B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1411253.6A GB201411253D0 (en) 2014-06-25 2014-06-25 Prodrug
IN2050/MUM/2014 2014-06-25
GB1411253.6 2014-06-25
IN2050MU2014 2014-06-25
GBGB1417646.5A GB201417646D0 (en) 2014-10-06 2014-10-06 Formulations of phosphate derivatives
GB1417646.5 2014-10-06
PCT/GB2015/051858 WO2015198059A1 (en) 2014-06-25 2015-06-25 Formulation comprising a gemcitabine-prodrug

Publications (2)

Publication Number Publication Date
BR112016025787A2 true BR112016025787A2 (pt) 2017-08-15
BR112016025787B1 BR112016025787B1 (pt) 2022-12-13

Family

ID=53499028

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016025787-1A BR112016025787B1 (pt) 2014-06-25 2015-06-25 Formulação farmacêutica compreendendo gencitabina-[fenil- (benzóxi-l-alaninil)]-fosfato, seu uso no tratamento de câncer, método de preparação e kit compreendendo a mesma

Country Status (29)

Country Link
US (4) US10117888B2 (pt)
EP (2) EP3269391A1 (pt)
JP (3) JP6855248B2 (pt)
KR (2) KR102421929B1 (pt)
CN (2) CN106470672B (pt)
AU (2) AU2015278900B2 (pt)
BR (1) BR112016025787B1 (pt)
CA (1) CA2944966C (pt)
CL (1) CL2016003261A1 (pt)
CY (1) CY1119772T1 (pt)
DK (1) DK3119794T3 (pt)
EA (1) EA033046B1 (pt)
ES (1) ES2655820T3 (pt)
HK (1) HK1244437A1 (pt)
HR (1) HRP20180007T1 (pt)
HU (1) HUE036011T2 (pt)
IL (2) IL248345B (pt)
LT (1) LT3119794T (pt)
MX (2) MX2020004054A (pt)
MY (1) MY186584A (pt)
NO (1) NO3119794T3 (pt)
PH (1) PH12016502552A1 (pt)
PL (1) PL3119794T3 (pt)
PT (1) PT3119794T (pt)
RS (1) RS56752B1 (pt)
SG (1) SG11201608809RA (pt)
SI (1) SI3119794T1 (pt)
TW (2) TWI765176B (pt)
WO (1) WO2015198059A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
DK2681227T3 (da) 2011-03-01 2016-02-22 Nucana Biomed Ltd Phosphoramidatderivater af 5-fluor-2'-deoxyuridin til anvendelse i behandlingen af cancer
JP2016506371A (ja) 2012-11-16 2016-03-03 ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド ヌクレオシドプロドラッグを調製する方法
HRP20230584T1 (hr) 2014-06-25 2023-09-15 NuCana plc Prolijekovi gemcitabina
JP6855248B2 (ja) 2014-06-25 2021-04-07 ヌカナ ピーエルシー ゲムシタビン−プロドラッグを含む製剤
GB201417644D0 (en) * 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
US10570168B2 (en) 2014-11-28 2020-02-25 NuCana plc 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds
CN106543252A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
CN112156102B (zh) 2015-09-16 2023-10-03 济南高合医疗科技有限公司 一种nuc-1031单一异构体的晶型及其制备方法
CN106543220A (zh) 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
KR20180063075A (ko) 2015-10-05 2018-06-11 뉴카나 피엘씨 조합 요법
HUE059026T2 (hu) 2015-12-11 2022-10-28 NuCana plc Foszfát-származékok és a gemcitabin-prodrug NUC-1031 diasztereoszelektív szintézise
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201522764D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
KR102657458B1 (ko) 2016-11-02 2024-04-12 센트렉시온 테라퓨틱스 코포레이션 안정한 수성의 캡사이신 주사 가능한 제형 및 이의 의학적 용도
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
BR112020000989A2 (pt) 2017-07-20 2020-07-14 Centrexion Therapeutics Corporation métodos e composições para tratamento de dor com o uso de capsaicina
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
CN109956986B (zh) 2017-12-22 2021-04-27 浙江柏拉阿图医药科技有限公司 肝递送吉西他滨前体药物核苷环磷酸酯化合物及应用
WO2023076878A1 (en) * 2021-10-26 2023-05-04 Emphascience Inc. Ready-to-dilute formulation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE212661T1 (de) 1998-01-23 2002-02-15 Newbiotics Inc Durch enzymkatalyse erhaltene therapeutische substanzen.
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
AU775601B2 (en) 1999-07-22 2004-08-05 Celmed Oncology (Usa) Inc. Enzyme catalyzed therapeutic activation
CN1181829C (zh) * 2000-11-03 2004-12-29 中国人民解放军军事医学科学院附属医院 吉西他滨溶液制剂
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
US20090022803A1 (en) 2005-01-27 2009-01-22 Erimos Pharmaceuticals Llc Oral Formulations For Delivery of Catecholic Butanes Including Ndga Compounds
CA2635797C (en) * 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
EP1913962A1 (en) 2006-10-22 2008-04-23 Ophir Perelson Expandable medical device for the treatment and prevention of cardiovascular diseases
WO2011008985A2 (en) * 2009-07-15 2011-01-20 Georgia Tech Research Corporation Methods and compositions for improved delivery of therapeutic and diagnostic agents
EP2501364A4 (en) * 2009-11-20 2012-10-24 Clavis Pharma Asa PARENTERAL FORMULATIONS FROM GEMCITABIN DERIVATIVES
CN101926757B (zh) * 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
KR101231925B1 (ko) * 2010-10-27 2013-02-08 씨제이제일제당 (주) 젬시타빈의 전구약물 및 이의 제조방법
WO2013107515A1 (en) * 2012-01-20 2013-07-25 Okapi Sciences Nv Eye drop composition
CN104955458A (zh) * 2012-11-07 2015-09-30 Z·索 取代的吉西他滨芳基酰胺类似物和使用所述类似物的治疗方法
JP2016506371A (ja) 2012-11-16 2016-03-03 ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド ヌクレオシドプロドラッグを調製する方法
BR112016011949A8 (pt) 2013-11-27 2020-04-28 Idenix Pharmaceuticals Llc composto, composição farmacêutica, e, uso dos mesmos”
JP6855248B2 (ja) * 2014-06-25 2021-04-07 ヌカナ ピーエルシー ゲムシタビン−プロドラッグを含む製剤
HRP20230584T1 (hr) 2014-06-25 2023-09-15 NuCana plc Prolijekovi gemcitabina
ES2830784T3 (es) 2014-07-22 2021-06-04 NuCana plc Proceso para la preparación de gemcitabina-[fenil(benzoxi-L-alanil)]fosfato
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
CN107835687A (zh) 2015-05-14 2018-03-23 努卡那有限公司 癌症治疗
KR20180063075A (ko) 2015-10-05 2018-06-11 뉴카나 피엘씨 조합 요법
HUE059026T2 (hu) 2015-12-11 2022-10-28 NuCana plc Foszfát-származékok és a gemcitabin-prodrug NUC-1031 diasztereoszelektív szintézise
AU2015418015B2 (en) 2015-12-23 2021-12-09 NuCana plc Combination therapy
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
US20190022117A1 (en) 2015-12-23 2019-01-24 NuCana plc Combination therapy
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives

Also Published As

Publication number Publication date
IL248345A0 (en) 2016-11-30
PL3119794T3 (pl) 2018-04-30
HK1244437A1 (zh) 2018-08-10
AU2015278900B2 (en) 2019-04-04
CA2944966C (en) 2022-10-25
US11707477B2 (en) 2023-07-25
TW201945007A (zh) 2019-12-01
EP3269391A1 (en) 2018-01-17
JP6855248B2 (ja) 2021-04-07
IL248345B (en) 2020-10-29
US20220031727A1 (en) 2022-02-03
EA201692422A1 (ru) 2017-04-28
US10786523B2 (en) 2020-09-29
IL276199B (en) 2022-04-01
LT3119794T (lt) 2018-02-12
CN106470672B (zh) 2019-11-05
DK3119794T3 (en) 2018-01-22
AU2015278900A1 (en) 2016-10-27
JP7329025B2 (ja) 2023-08-17
JP2020079255A (ja) 2020-05-28
TWI674097B (zh) 2019-10-11
CY1119772T1 (el) 2018-06-27
US11040051B2 (en) 2021-06-22
CL2016003261A1 (es) 2017-10-06
WO2015198059A1 (en) 2015-12-30
JP6970221B2 (ja) 2021-11-24
ES2655820T3 (es) 2018-02-21
JP2022031659A (ja) 2022-02-22
TWI765176B (zh) 2022-05-21
EP3119794A1 (en) 2017-01-25
TW201613611A (en) 2016-04-16
RS56752B1 (sr) 2018-04-30
US20190022118A1 (en) 2019-01-24
PT3119794T (pt) 2018-01-15
US10117888B2 (en) 2018-11-06
EP3119794B1 (en) 2017-10-11
SG11201608809RA (en) 2016-11-29
NZ725009A (en) 2021-02-26
AU2019204557A1 (en) 2019-07-18
US20170095498A1 (en) 2017-04-06
MY186584A (en) 2021-07-28
MX2016015629A (es) 2017-08-02
PH12016502552A1 (en) 2017-04-10
KR20170042501A (ko) 2017-04-19
IL276199A (en) 2020-09-30
JP2017519022A (ja) 2017-07-13
KR20220104270A (ko) 2022-07-26
CA2944966A1 (en) 2015-12-30
HRP20180007T1 (hr) 2018-02-23
CN110882268A (zh) 2020-03-17
HUE036011T2 (hu) 2018-06-28
KR102421929B1 (ko) 2022-07-15
CN106470672A (zh) 2017-03-01
MX2020004054A (es) 2021-11-30
BR112016025787B1 (pt) 2022-12-13
AU2019204557B2 (en) 2020-08-27
NO3119794T3 (pt) 2018-03-10
US20200397810A1 (en) 2020-12-24
EA033046B1 (ru) 2019-08-30
SI3119794T1 (en) 2018-02-28

Similar Documents

Publication Publication Date Title
BR112016025787A2 (pt) Formulação farmacêutica compreendendo gencitabina-[fenil- (benzóxi-l-alaninil)]-fosfato, seu uso no tratamento de câncer, método de preparação e kit compreendendo a mesma
CL2018000813A1 (es) Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso.
EP3302442A4 (en) PHARMACEUTICAL FORM AND USE THEREOF
GB201411465D0 (en) Active pharmaceutical ingredient (api) comprising cannabinoids for use in the treatment of cancer
BR112016030787A2 (pt) entidade química, composição farmacêutica e seu uso
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
BR112016020199A2 (pt) Composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
BR112016030968A2 (pt) análogos de pridopidina, preparação e uso destes
IL258246B (en) Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer
BR112016027041A2 (pt) Combinações farmacêuticas para tratamento do câncer
IL266198A (en) Liposomal formulation for use in cancer treatment
HK1223304A1 (zh) 包含二甲雙胍和二氫槲皮素的藥物組合及其用於治療癌症的用途
BR112016027043A2 (pt) Combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112016026545A2 (pt) eribulina ou um sal farmaceuticamente aceitável do mesmo, seus usos e kit para utilização no tratamento de câncer da mama
EP3348206A4 (en) DEVICE FOR RELEASING A THERAPEUTIC ACTIVE DEVICE AND KIT FOR RELEASING A THERAPEUTIC AGENT
MA45187A (fr) Combinaisons pharmaceutiques
EP3359962A4 (en) BLOOD PREPARATION AND PROFILING
BR112017001384A2 (pt) composto para uso em tratamento anti-helmíntico
EP3337784A4 (en) USE OF UREIDOMUSTIN (BO-1055) IN THE TREATMENT OF CANCER
MA50358A (fr) Sémaglutide en thérapie médicale
IL249860A0 (en) Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer
EP3375445A4 (en) USE OF AKT2 IN THE DIAGNOSIS AND TREATMENT OF A TUMOR
PL3250181T3 (pl) Formulacja farmaceutyczna na bazie minoksydylu do stosowania miejscowego i jej zestaw
EP3560527A4 (en) ACTIVE INGREDIENT FOR TISSUE HEALING
IL237283A0 (en) Dldh and its derivatives, and preparations containing them for medical use

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25D Requested change of name of applicant approved

Owner name: NUCANA PLC (GB)

B25G Requested change of headquarter approved

Owner name: NUCANA PLC (GB)

B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07H 19/10 , A61K 31/7068 , A61P 35/00 , A61K 9/00 , A61K 47/16 , A61K 47/20 , A61K 47/22 , A61K 9/08

Ipc: A61K 31/7068 (2006.01), C07H 19/10 (2006.01), ...

B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/06/2015, OBSERVADAS AS CONDICOES LEGAIS